Current Highlighted Clinical Trials

1. Sentinel lymph node biopsy in early-stage Merkel cell carcinoma (Biopsy ME)
3. A phase 3 randomized, open label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not eligible for transplant (IMROZ study)
4. A randomized phase 2 trial of $^{177}$Lu-PSMA617 theranostic versus cabazitaxel in progressive metastatic castration resistant prostate cancer (ANZUP protocol 1603) (TheraP)
5. A randomised Phase II, trial of imatinib alternating with regorafenib compared to imatinib alone for the first line treatment of advanced gastrointestinal stromal tumour (ALTGIST)
6. Molfirinox And STErerotactic Radiotherapy for Patients with Locally Advanced pancreas cancer (MASTERPLAN): a feasibility study (FMISO & FDG Scans)
7. A Phase Ib Multi-Cohort Trial of MK-3475 (pembrolizumab) in subjects with Hematologic Malignancies (MK3475-013)
8. To evaluate the utility of parametric MRI and PET-CT for assessment of tumour response and normal tissue changes post lung SABR (Stereotactic Ablative Body Radiotherapy).
9. A Phase 3, Double-blind Placebo-controlled study of Quizartinib (AC220) administered in combination with induction and consolidation chemotherapy, and administered as maintenance therapy in subjects 18 to 75 years old with newly diagnosed FLT3-ITD acute myeloid Leukemia (QuANTUM-First)
10. Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases (CORE)
11. A Phase 1, Open-label dose escalation study of the safety and Pharmacokinetics of HMPL-513 in patients with relapsed or refractory B-cell Non-Hodgin's Lymphomas or Chronic Lymphocytic Leukaemia (HMPL 523)
12. TROG12.02 –PET Scans for Locally Advanced Breast Cancer and Diagnostic MRI to Determine the Extent of Operation and Radiotherapy (PET LABRADOR).